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ABSTRACT: In the last decade, interest in the field of three-dimensional (3D) bioprinting has increased 
enormously. 3D bioprinting combines the fields of developmental biology, stem cells, and computer 
and materials science to create complex bio-hybrid structures for various applications. It is able to 
precisely place different cell types, biomaterials and biomolecules together in a predefined position to 
generate printed composite architectures. In the field of tissue engineering, 3D bioprinting has 
allowed the study of tissues and organs on a new level. In clinical applications, new models have been 
generated to study disease pathogenesis. One of the most important components of 3D bio-printing is 
the bio-ink, which is a mixture of cells, biomaterials and bioactive molecules that creates the printed 
article. This review describes all the currently used bio-printing inks, including polymeric hydrogels, 
polymer bead microcarriers, cell aggregates and extracellular matrix proteins. Amongst the polymeric 
components in bio-inks are: natural polymers including gelatin, hyaluronic acid, silk proteins and 
elastin; and synthetic polymers including amphiphilic block copolymers, PEG, poly(PNIPAAM) and 
polyphosphazenes. Furthermore, photocrosslinkable and thermoresponsive materials are described. 
To provide readers with an understanding of the context, the review also contains an overview of 
current bio-printing techniques and finishes with a summary of bio-printing applications.  
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INTRODUCTION 
Additive manufacturing (AM), more commonly known as 3D printing, is a rapidly growing field of 
interest that fabricates physical objects by depositing material layer-by-layer according to a digital 
model. In the biomedical field, 3D bioprinting refers to several different AM techniques, which are 
able to print not only materials but also living cells, in a specified location. 3D bioprinting was first 
demonstrated in 1988 by Klebe,1 who used the term ‘cytoscribing’ to describe the technique of the 
precise positioning of cells on a 2D substrate using a computer-controlled ink jet printer or graphics 
plotter. As more research groups joined, the technique evolved and the first international workshop 
on bioprinting and biopatterning was held in 2004 at the University of Manchester.2 Between 2012 
and 2015, the number of papers referring to bioprinting increased fourfold and new journals were 
introduced.3 Currently, the field is expanding at a rapid rate.  
The reason for the increasing popularity of 3D bioprinting is its tremendous potential. The aim 
of 3D bioprinting is to construct, in vitro, tissues, organs and other biological systems that mimic their 
native counterparts.4 The materials used consist of natural and synthetic polymers, living cells, drugs, 
growth factors and genes. When deposited in a precise and controlled way, these allow the fabrication 
of not only scaffolds and scaffold-free tissues, but also mini-tissues and organ-on-a-chip models 
through different techniques.5, 6 Depending on the type of tissue and aim of the fabrication, different 
bioprinting techniques can be used, including droplet-based, extrusion-based, laser-induced forward 
transfer, and integrated bioprinting. Each printing technique is based on different physical processes 
which define the criteria (i.e. rheology profile, photoreactivity, thermal and oxidative stability) of a 
suitable bioink. Due to its ability to precisely print cells whilst maintaining cell viability, 3D printed 
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tissues can be used in tissue engineering and regenerative medicine, transplantation, drug testing and 
high-throughput screening, and cancer research.  
In tissue engineering and regenerative medicine, 3D bioprinting allows the development of 3D 
tissue models that can replace current 2D cell culture and animal models for in vitro drug testing. 
Animals respond differently to drug candidates compared to humans and therefore can be ineffective 
as models of human diseases.5 3D bioprinting can, furthermore, be used to print bone and cartilage 
for musculoskeletal injury repair. In in-situ bioprinting, the bio-ink is directly printed into the lesion 
sites during surgery, which places additional scrutiny on aspects of sterility and biocompatibility. 
Due to a scarcity of patient-compatible donor tissue and organs, there is an increasing demand 
for tissue engineering solutions, including 3D bioprinted tissues. Through 3D printing, personalized 
tissues can be fabricated using anatomical 3D image analysis and computed tomography techniques.4, 
7 However, the technique is still at its early stage and many challenges have to be faced for 
transplantation and other applications.  
Human tissues consist of many different cell types and are vascularized to allow transport of 
nutrients, oxygen and waste products. For successful tissue replacement in human patients, a vascular 
system has to be built-in at a single-cell level and heterocellular tissue patterning should be 
anatomically accurate.5, 8-10 Furthermore, the materials used should be biocompatible, biodegradable, 
and should not have any toxic effect, including their waste compounds and intermediates. Bio-inks 
that are consistent with these requirements should also be bioprintable and enable rapid cell growth 
and proliferation.5 Besides the materials used to create the neo-tissue, the printing technique itself 
(resolution, speed, and bioprinting processes) must also be optimized to allow fabrication of complex 
tissues at various scales.4 3D bioprinting has several advantages in this context. There is precise 
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control over size, microarchitecture and cellular composition.11  It has a high-throughput capability in 
tissue model fabrication. Cells can be co-cultured with a low risk of cross-contamination.12 Printed 
tissues should recreate the complexity and heterocellularity of native tissues. 3D bioprinting enables 
vascularization within the printed tissue, although this has to be explored further.   
3D bioprinting is an interdisciplinary field, requiring knowledge from developmental biology, 
stem cell science, chemistry, computer science, and materials science.13 To fabricate complex tissues 
that can be used for tissue replacement or for drug testing models, several conditions must be kept in 
mind.6 There is a wide selection of materials that can be used for the bio-ink and scaffold; depending 
on the type of tissue, different cell types are needed. Stem cells have to differentiate into the cell type 
of interest, for which growth and differentiation factors are needed. In order to fabricate a 3D 
bioprinted tissue, cells have to survive the printing process, for which the sensitivity and protection of 
the cells is important. Cell viability after bio-printing can be identical to that obtained using the same 
bio-ink in a manual scaffolding process, depending on the type of bio-ink and printing process used14. 
The bioprinter itself thus plays an important role in the fabrication process. As tissues and organs are 
highly complex, a bioprinter should be able to print these different cell types and accompanying 
biomaterials at the same time.11 The printed structure should be of a high resolution, which is also 
dependent on the accuracy of the printer. Other requirements of a bioprinter include: sufficient build 
speed, user friendliness, full automation capability, ease of sterilization, affordability, versatility, and 
compactness.15   
This review focuses on the materials used in 3D bio-printing: the ‘bio-inks’. Current advances 
and limitations will be discussed as well as future perspectives. It is complementary to the excellent 
recent review on bio-inks by Ozbolat et al., which provides a practical comparison between different 
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types of bio-inks.16 In our review, we have included sections describing current bioprinting techniques 
and applications of 3D bioprinting, to enable the reader to understand better the context. 
 
BIOPRINTING TECHNOLOGY 
For the fabrication of 3D bioprinted constructs, the bio-ink and bioprinter are key elements. Important 
factors such as strength, resolution and shape are dependent on the fabrication method. Below, an 
overview of the most important bioprinting technologies are discussed. The main technologies are 
droplet-based, extrusion-based, laser-induced forward transfer, stereolithography, and integrated 
bioprinting (Figure 1).  For a more thorough explanation of any of these technologies, the reader is 
directed to the recent review of Jungst et al.17  
 
Droplet-based bioprinting 
Droplet-based bioprinting (DBB), first introduced in the early 2000s,11 is a simple and agile 
technique with which biologics can be deposited in a precise and controlled way. Picolitre droplets are 
layered on top of a substrate without contact between the nozzle and the substrate.18 DBB is highly 
versatile as it is compatible with many biological materials, it can print inks with low viscosities (3.5-12 
mPa.s-1), and it enables a high speed and high resolution.5, 11 However, it faces some challenges. The 
uniformity of the droplets needs to be improved and encapsulation of cells is inconsistent.11 
Furthermore, bioprinted constructs have a limited mechanical and structural integrity.5 Cross-
contamination of bio-inks when printed simultaneously restricts the size of the constructs as 
vascularization and porosity are hard to control.5, 11  DBB can be subdivided into three categories; 
inkjet, acoustic, and micro-valve bioprinting (Figure 2).  
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Inkjet bioprinting 
Inkjet bioprinting is the most common form of DBB.11 It includes continuous-inkjet, drop-on-
demand inkjet, and electrodynamic inkjet bioprinting. In continuous-inkjet bioprinting, the bio-ink 
solution in the chamber is extruded through a nozzle causing the stream to break up into droplets, 
due to the Rayleigh-Plateau instability (Figure 2A1).5 The drop-on-demand (DOD) inkjet technique 
generates droplets using thermal or piezoelectric actuators, or electrostatic forces. This technique is 
preferred over continuous-inkjet bioprinting as it only generates droplets when required.5 Droplets are 
generated by the breaking of surface tension rather than an applied pressure. Advantages of this 
technique are its low cost, high resolution (20-100µm) and deposition of multiple types of materials 
by using multiple nozzles.18  The technique however has disadvantages. There is a narrow material 
selectivity as the technique only works for low viscosity liquids. The small size of the droplets increases 
the processing time and the printed tissue has weak mechanical properties.18 
One way of generating droplets in DOD is through heating. When a voltage pulse is applied, 
the bio-ink solution is locally heated, producing a vapour bubble that then expands rapidly and bursts. 
The pressure produced by this pulse will at some point overcome the surface tension at the nozzle 
orifice, causing droplet ejection (Figure 2A2).5 A great advance of this technique is that the integrity of 
stem cells is maintained; studies showed no loss in functionality and differentiation capacity, or a 
change in genotype and phenotype.19, 20 
In piezoelectric-induced droplet formation, a piezoelectric actuator causes deformation in the 
fluid chamber after a pulse is applied5. The sudden change causes a pressure wave, which overcomes 
the surface tension at the nozzle orifice and causes droplet ejection (Figure 2A3). This technique 
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results in high resolution patterns, but a decreased cell viability compared to other techniques.18 An 
electrostatic printed droplet is generated by a temporal increase in volume of the fluid chamber, 
caused by applying a voltage pulse between an electrode and a pressure plate. The pressure plate 
deflects, and restores to its original position when the pulse extinguishes. The increase in volume 
caused by the pressure plate causes ejection of the droplets (Figure 2A4).5 
 The third subset of inkjet bioprinting is electrohydrodynamic jet bioprinting, which uses an 
electric field to pull the droplet through the nozzle orifice. An advantage of this approach is the ability 
to use small nozzle orifice diameters and highly concentrated bio-inks.5 However, due to the large 
shear forces produced from the high pressure on the droplets and the minuscule orifice diameter, cells 
can be damaged.5 In the resting phase, the bio-ink is pushed to the orifice by a certain back-pressure 
so the bio-ink will form a spherical meniscus at the tip due to surface tension. A high voltage (0.5-
20kV) is applied between the nozzle and the substrate, creating an electric field that causes the 
mobile ions in the bio-ink to accumulate near the surface of the meniscus. Due to Coulombic or 
electrostatic repulsions between these ions, the meniscus is deformed into a conical shape, the Taylor 
cone.5 When the electrostatic stresses overcome the surface tension the droplet is ejected (Figure 
2A5). Different jetting modes can be used with this technique and are dependent on the applied 
voltage, bio-ink properties, and bio-ink flow rate. These factors also determine the cell viability. At low 
voltages and flow rates, the printer is in dripping mode. For a more distinct stream of droplets, 
intermediate voltages and/or flow rates can be applied. For a continuous stream of bio-ink, a high 
voltage must be applied. The latter mode, also known as the cone-jet-mode, has a continuous 
presence of the Taylor cone.5 The droplet size increases with the applied voltage. Droplet size is 
important in electrohydrodynamic jet bioprinting, as the media transport will be ineffective when it 
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exceeds 400 µm. Media transport is also affected by the bio-ink constituents, which affect the 
diffusion of the media, together with the cell concentration. Cell concentration, bio-ink constituents 
and the applied voltage together affect the long-term fate of the post-bioprinting cell. In general, the 
stream of droplets and continuous modes are used more often than the dripping mode. This makes 
this bioprinter less suitable for printing tissues that require accurate placement of the cells.5 
 
Acoustic-droplet-ejection bioprinting  
In acoustic-droplet-ejection bioprinters, the bio-ink is not exposed to stressors like heat, high pressure, 
high voltage or shear stress as in inkjet bioprinting. Rather, the bio-ink is kept in an open pool and 
droplets are produced through acoustic waves. The bio-ink in the reservoir is held in place due to the 
surface tension at a small exit channel. The bioprinter contains a single channel or an array of these 
2D microfluidic channels. The acoustic actuator consists of a piezoelectric substrate with interdigitated 
gold rings placed upon it, which generate acoustic waves on demand on the surface (Figure 2B).5 The 
generated circular waves move from the air-bio-ink interface down toward the exit channel to form an 
acoustic focal point. When the force of this focal point exerts the surface tension at the exit channel, a 
droplet will be ejected.5 As the acoustic waves are critical for droplet ejection, any disturbances by a 
moving print head and/or substrate can interfere with the printing process by losing control over 
droplet ejection. Another disadvantage of the acoustic bioprinting technique is the inability to print 
with viscous bio-inks containing a high cellular concentration, such as commonly used hydrogels.5  
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Micro-valve bioprinting 
 In a micro-valve bioprinter, droplets are generated by the opening and closing of a microvalve 
under pneumatic pressure.18 The printer contains a solenoid coil and a plunger that blocks the orifice. 
When a voltage pulse is applied, the valve coil at the top of the print head will generate a magnetic 
field which pulls the plunger upwards, unblocking the exit. When the back pressure in the bio-ink 
chamber is large enough and exceeds the surface tension, the bio-ink is ejected (Figure 2C).5  This can 
either be in a continuous or dripping mode, depending on the back pressure and valve-gating time.  
 The droplet volume and cell viability are dependent on the pneumatic pressure of the 
microvalve, the nozzle geometry, the cell concentration, and the bio-ink constituents.5  The volume of 
micro-valve bioprinter droplets are generally larger when identical nozzles are used, in comparison 
with other DBB techniques,5 which reduces resolution. The cells printed through micro-valve 
bioprinting retain their function, are able to proliferate, and their genotype and phenotype are 
preserved.21 Studies have shown that the differentiation capacity of stem cells is unaffected by the 
printing process.22, 23 These characteristics make micro-valve bioprinting favorable for printing various 
types of cells and proteins.  
  
Extrusion-based bioprinting  
Extrusion-based printing was introduced in the early 2000s and is the most common and affordable 
bioprinting technique.11 It is able to fabricate 2D and 3D structures by continuous dispersion of a 
hydrogel containing cells through a micro-nozzle.18 Extrusion-based printers disperse the bio-ink 
through a pneumatic or mechanical system.24 The 2D patterns are created by physically or chemically 
solidifying the hydrogels. By stacking these 2D patterns, 3D structures can be created.18 The 
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advantages of this technique are the ability to deliver multiple cells and materials, and there is a wide 
material selectivity. It has the ability to disperse high viscous bio-inks with high cell densities, cell 
pellets,25 tissue spheroids,26, 27 and tissue strands.28 Furthermore, the production is scalable and 
synthetic polymers can be used. A great advantage is the high cell viability, typically above 90%.18 The 
technique however has a downside, as it has a relatively low resolution (>100µm). Ozbolat et al. 
created an extrusion-based ‘Multi-arm Bioprinter’ that is capable of multi-material deposition, has a 
reduced fabrication time, while being able to process multiple cell types at the same time29. This 
enables the printer to fabricate complex structures that can be organized like native tissue.  Several 
tissue types have already been explored for extrusion-based bioprinting, including cartilage30, 31, heart 
valve conduits32, 33, and neuronal tissue25, 34.  
 Very recently, Liu et al. created a rapid continuous multimaterial extrusion bioprinter that is 
able to print up to 7 different types of bio-inks without the need to switch nozzles.35 The printer 
consists of different channels, each connected to its own bio-ink reservoir. Software is used to open 
the valves to deposit the different inks at the desired moment through a digitally tunable pneumatic 
single-printhead system. The advantage of this approach is the almost complete absence of a gap 
between the switching processes.35 In order to test their printer, Liu et al. printed a range of complex 
3D structures from multilayer cubes composed of 2 or 3 different bio-inks to human organ-like 
constructs from multiple bio-inks (Figure 3). 
 
Laser-induced forward transfer bioprinting 
Laser-induced forward transfer (LIFT) bioprinting was first introduced in 199936 for the deposition of 
inorganic materials and was soon after adapted for bioprinting.37 The system contains a donor layer 
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with a ribbon structure, containing an energy-absorbing layer (gold or titanium), which responds to 
laser stimulation.38 A layer of bio-ink is suspended on the bottom of the donor layer. During printing, a 
laser pulse is applied on the donor layer, heating a small portion. This creates a high-pressure bubble 
as part of the donor layer will evaporate. The high-pressure bubble puts pressure on the bio-ink layer, 
which propels the bio-ink towards the substrate underneath it. The bio-ink falling on the substrate will 
then immediately be crosslinked.38 This non-contact printing method has a few advantages. First of all 
there is no contact between the dispenser and the bio-inks, taking away a contamination source. 
Furthermore, highly viscous materials can be used and the cell viability is high (>95%).38 However, the 
laser can potentially damage the cells and the technique has a high associated cost. For these reasons 
only a few groups have investigated the capabilities of laser-induced forward transfer bio-printing. A 
LIFT study by Koch et al.39 showed a survival rate of 98% for skin cells (fibroblasts, keratinocytes) and 
over 90% for human mesenchymal stem cells (hMSCs). Furthermore, all maintained their ability to 
proliferate and did not show any increase in apoptosis or DNA fragmentation.  
 
Stereolithography 
Another interesting bio-printing method is stereolithography which uses light to selectively crosslink 
bio-inks in a layer-by-layer process.24 Instead of heating a donor layer as in laser-induced forward 
transfer printing, stereolithography uses a laser or digital light projector to photolytically crosslink the 
bio-inks, enabling it to crosslink a layer in a single printing plane.38 The print head, therefore, only has 
to move in one direction. Advantages of stereolithography are its high resolution (<100µm), short 
printing time (<1h), and high cell viabilities (>90%).38   
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Integrated bioprinting 
A general disadvantage of all bioprinting techniques is the low strength of the printed structures. 
Different research groups therefore have created hybrid techniques to improve the mechanical 
properties of the resulting constructs. For instance, Kang et al. created a hybrid system able to print 
with a synthetic biopolymer and a cell-laden hydrogel to fabricate a tissue construct with high 
mechanical strength.18  In 2014, Pati et al. introduced a hybrid technique that could print relatively 
stiff biodegradable thermoplastic polymers and hydrogels containing decellularized extracellular 
matrix (dECM).40 To be able to print human-scale functional tissue constructs, Kang et al. developed 
the integrated tissue-organ printer (ITOP). This printer was able to fabricate mandible and calvarial 
bone, cartilage and skeletal muscle.41 
 
Design and printing strategies  
The process capabilities of a bioprinter and design strategies are very important for 3D bioprinting.42 
Important design factors include shape and resolution, material heterogeneity, and cellular-material 
remodeling dynamism. Specific process capabilities, parameters and features should be mapped into 
these design factors. For successful bioprinting, design, technology and material selection should be 
considered carefully as these factors affect the integrity of the bioprinted structure. An in-depth 
discussion of these factors is beyond the scope of this review, for further information the reader is 
directed to the recent review by Lee et al.42 
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BIO-INKS 
Bio-inks are biomaterial solutions containing the living cells and so are key components in bioprinting. 
It is important that the materials present in the biomaterial solution protect the cells against stressors 
during the printing process. The four main types of bio-ink materials are hydrogels, microcarriers, cell 
aggregates, and decellularized matrix components.11, 43 Cell aggregates can be further classified into 
three subsets: tissue spheroids; cell pellets; and tissue strands.11  
 In DBB, besides protecting the cells against stressors, bio-ink droplets should also result in 
precise deposition. An important characteristic for this is droplet integrity, which can be altered by the 
material components of the bio-ink.5 If this integrity is lost, the droplet can splash or spread, either 
displacing the deposited cells from their desired position or causing structural failure.5 After collision 
with the substrate, a droplet can disintegrate into secondary droplets (splashing), or expand its surface 
area (spreading). The type of collision is dependent on the droplet size, density, and surface tension.5 
 In extrusion-based printing, bio-inks should have certain viscoelastic characteristics, including 
shear-thinning and self-healing properties.24 Shear-thinning is important for the extrusion of the bio-
ink at low nozzle pressures to protect the cells against physical stressors. The bio-ink should then be 
able to self-heal to keep an integer 3D printed structure.24 For a structurally stable complex with 
mechanical integrity, the bio-ink should harden, in a cytocompatible manner, immediately after 
printing. In tissue regeneration, the scaffold structure should be degraded by the body to allow 
integration of the new tissues.24  
In tissue engineering, constructs are needed with which to fabricate both hard and soft tissues. 
Many studies have already shown the potential in hard tissue engineering by the fabrication of tissues 
like cartilage and bone.44-46 However, challenges still remain. For instance, patient-specific treatment 
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needs optimization and, more importantly, printing of large size and uniform constructs has not yet 
been achieved.4 A specific challenge lies in soft tissue engineering. As soft tissues have a combination 
of highly elastic, flexible and viscous properties, stacking of layers is difficult.6 For both hard and soft 
tissue engineering, different bio-inks can be used to create a structure with the right properties for a 
certain application. Several types of bio-inks will be discussed below (the properties and 
characteristics of the materials used in bio-inks are summarised in Table 1). 
 
Hydrogels 
A commonly used material for bio-inks are hydrogels, which are hydrated networks of crosslinked 
natural or synthetic polymers. The hydrophilic nature of these polymers allows the gel to swell in an 
environment with a high water content. Hydrogel materials can be both highly biocompatible and 
biodegradable, a necessity for in vivo applications. Furthermore, cells can be encapsulated in 3D when 
the hydrogel undergoes gelation.6, 47, 48 The environment created does not affect cell-cell 
interactions.49 A disadvantage of hydrogels, however, is their weak mechanical properties. They often 
do not maintain their designed shape.50 Whether a hydrogel is suited or not for 3D bioprinting 
depends mainly on its rheological properties and the crosslinking method employed, which can be 
both physical and chemical in nature.51 Several properties that influence printability and cell survival 
are summarized in Figure 4, these include gelation, viscosity, nozzle gauge, shear stress, network 
properties, and fabrication time.51 
The residual structural and mechanical properties in the printed article are highly important for 
3D bioprinting, as without these characteristics the function of the construct is lost. Several hydrogels 
have been explored employing a divergent set of synthetic and natural polymers, with and without 
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crosslinking to control properties.6 The advantages of synthetic materials are that they can be tailored 
with specific physical properties, they have robust mechanical properties and good control over 
degradation time after the tissue is fully regenerated.6 A downside, however, is the often poor 
biocompatibility, non-natural degradation products, and a loss of mechanical properties during 
degradation.6 Due to these reasons, natural biomaterials like collagen are preferred in some cases 
over synthetic polymers as they are biodegradable and non-toxic. Of the natural polymers, exogenous 
collagen has been shown to be highly biocompatible and has been observed to have very weak 
antigenic properties.6, 52 
 
Thermo-responsive inks 
Almost all bioprinting techniques disperse the bio-ink through a nozzle onto the substrate. To 
obtain a clear image, the bio-ink should move through the nozzle easily but should become rigid upon 
dispersion. Thermo-responsive hydrogel inks have the advantageous property of tunability of their sol-
gel state by changing the temperature.53 Thermo-responsive polymers in these bio-inks consist of 
hydrophilic homopolymers or block copolymers that maintain a colloidal solution (sol) form at room 
temperature and form a gel at body temperature.54 This allows easy, accurate printing in its sol state 
and a simple switch in temperature causes rapid gelation leading to high resolution printing.53 Cells 
cultured on these thermo-responsive hydrogels form self-supporting sheets by producing their own 
extracellular matrix (ECM); the cell sheet can be detached from the substrate simply by reducing the 
temperature.55 Naturally-derived thermo-responsive polymers have the advantage of being 
biocompatible, while synthetic polymers mostly have a higher mechanical strength. Both types of 
thermo-responsive polymers will be discussed below.  
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Natural and naturally-derived polymers 
Gelatin is a collagen derivative that can be used in different bioprinting techniques, like 
extrusion-based,56 piezo-electric inkjet,57 and two-photon polymerization.58 Gelatin itself has a 
random coil structure in solution and forms a helix below 35°C where helix-chain aggregation causes 
gelation.53 To stop the liquification of gelatin above 35°C, it is most commonly modified with a 
methacrylate group, creating the photopolymer gelatin methacrylate (GelMa).36, 59 Billiet et al. 
prepared photocrosslinkable GelMa interconnected porous constructs.60 GelMa was used by Kolesky 
et al. to make ECM-like ink to support cells.56 Both studies showed a high cell viability of over 95%. 
Gelatin naturally contains integrin-binding motifs, like arginine-glycine-aspartic acid (RGD), which 
allow cells to adhere and spread. Matrix metalloproteinase (MMP) sensitive degradation sites present 
in GelMa play an important role in the proliferation and migration of cells,61 as MMPs cleave ECM 
components to allow cells to expand, reposition and proliferate.62  Skardal et al. made use of the 
photocrosslinkable property of GelMa by co-crosslinking with methacrylated hyaluronic acid (HAMA) 
to yield an extrudable gel-like fluid for the two-step bioprinting of tubular constructs.63 The bio-ink 
was biocompatible, allowed cell adhesion and cell proliferation, and showed no inflammatory 
response after subcutaneous injection into nude mice. The printed tubular construct contained viable 
cells that naturally secreted ECM to substitute the synthetic ECM environment. A printing method 
using gelatin called freeform reversible embedding of suspended hydrogels, or FRESH, was developed 
by Hinton et al.64 In this technique, hydrogels are printed within a second hydrogel that is used as a 
support bath to improve print fidelity. This support bath consists of gelatin microparticles that act like 
a Bingham plastic, meaning that during printing the particles act like a fluid due to the high shear 
stresses but become rigid at the low shear stresses in the bath. Myoblasts in suspension printed with 
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FRESH showed a 99.7% viability. Although most articles using GelMa do not specify the type of GelMa 
used, gelatin comes in two types. Gelatin from acid treatment generates type A, while an alkali 
treatment will yield type B.65 Lee et al. studied the characteristics of both types of GelMa as these 
influence the properties of GelMa and thus its printability. They showed a higher methacrylation of 
type B, although type A showed a higher resolution after extrusion printing. Both types of GelMa 
showed a cell viability of around 75% in cell-laden printed constructs.65 Jia et al. designed a cell-
responsive bio-ink by using GelMa combined with sodium alginate and 4-arm poly(ethylene glycol)-
tetra-acrylate (PEGTA).66 This bio-ink was firstly crosslinked ionically with calcium ions, followed by 
covalent photocrosslinking of the GelMa with PEGTA. Extrusion printing of the bio-ink created vascular 
constructs promoting cell adhesion, proliferation and migration with a cell viability exceeding 80%. 
Another GelMa blend was made by Kang et al., who used GelMa in composition with poly(ethylene 
glycol) (PEG) diacrylate/alginate.41 By testing different valve cell types and photo-initiators, they 
identified parameter combinations for high cell viabilities (93-95%). Decreased cell viabilities were 
found in photocrosslinked inks due to a higher general oxidative stress level and most possibly other 
stress mechanisms. An additional challenge lies in the design of bio-inks for cardiac tissue constructs. 
Electrical coupling between cells is crucial for a functional cardiac tissue. Zhu et al. therefore created a 
cytocompatible bio-ink with a conductive component and a cell viability of over 70% by incorporating 
gold nanorods (GNRs) into a GelMa-based bio-ink. Cetyltrimethylammonium bromide (CTAB)-coated 
commercial GNRs were coated with GelMa to improve biocompatibility, then were mixed with a 
solution of GelMa and photo-initiator to create a prepolymer bio-ink capable of printing synchronized 
contracting cardiac tissue.67  
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Collagen is part of the ECM that provides structural and biochemical support to the 
surrounding cells. Collagen types I, II, and III are found in hard and soft connective tissues. A collagen 
molecule consists of three polypeptide chains that each form a helical structure.68 The chains contain 
RGD residues that form a motif able to adhere cells via integrin-RGD binding.6 Collagen is a 
biodegradable protein with little toxicity and so it is a widely used material for bioprinting. As part of 
the ECM, collagen can provide stability to 3D printed tissues as a surrounding scaffold.69 Lee et al. 
showed the potential of collagen for tissue engineering by creating a human skin model with collagen 
as representation of the dermal matrix with fibroblasts and keratinocytes showing cell viability of 
around 98%.10 Skardal et al. combined fibrin and collagen in one bio-ink together with amniotic fluid-
derived (AFS) cells or bone marrow-derived MSCs.70 After deposition into skin wounds, the cell-
containing bio-inks showed an increase of wound closure and angiogenesis compared to the control. 
The AFS cells showed the highest amount of angiogenesis which is probably caused by secretion of 
growth factors by these cells. Rhee et al. developed soft tissue implants with high-density collagen 
hydrogels loaded with meniscal fibrochondrocytes for load-bearing applications.71 Cells had a viability 
of around 90% directly after printing and maintained a high viability over 10 days in culture. Kim et al. 
also studied the use of a genipin-crosslinked collagen-based hydrogel to produce a porous and 
mechanically strong construct.72 Osteoblast-like cells and human adipose stem cells were combined 
with the collagen bio-ink to create a 3D construct with 95% cell viability and extensive cell 
proliferation. Collagen is also widely used as a biomaterial for wound healing, as a component of 
sponges, hydrogels, membranes, wound dressings, and in direct skin replacement. A collagen mimetic 
protein can even be used to anchor cytoactive agents in damaged tissue to promote wound healing.73 
Collagen can also be used in osteochondral tissue regeneration. Park et al. printed osteoblast-
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encapsulated Col-1 hydrogels and chondrocyte-encapsulated HA hydrogels creating 3D osteochondral 
mimicking structures with a cell viability of more than 90% for both cell lines.74 Shim et al. created an 
MSC-laden hydrogel consisting of two ECM materials, atelocollagen and HA, which enabled 
osteochondral tissue regeneration in the knee joints of rabbits.75 The group of Cho used a collagen 
bio-ink containing three different cell types infused in a framework of poly(ε-caprolactone) (PCL) to 
create a 3D liver microenvironment. The printed structure contained a capillary-like network and 
showed hepatocyte growth with a viability of 92-99%, demonstrating the ability to create multicellular 
3D liver constructs.76  
Elastin is a protein that is present in elastic fibers, which can be found in tissues that need to 
be able to recover from deformation.77 Elastin is formed from tropoelastin, the monomer of the 
elastin polymer. Each monomer consists of a hydrophobic domain (mostly valine, glycine, and proline) 
and a hydrophilic domain (mainly lysine and alanine).78 Natural elastin is hard to extract, so a synthetic 
naturally inspired polymer is used. These elastin-like peptides (ELPs) are obtained by expression in E. 
Coli and purification of the cell lysates.77 They are therefore also known as elastin-like recombinamers 
(ELRs).79 Thermo-responsive inks can be created with ELRs as they undergo sol-gel transition at 
increased temperature. The random-coil ELRs hydrophobically fold into ordered β-spirals upon 
heating.77 
Silk from the silkworm contains two proteins, sericin and fibroin. The fibroin part of silk can be 
used in hydrogels. Fibroin consists of a light and heavy chain bound by disulfide bonds and consists of 
a repeating pattern of Gly-Ser-Gly-Ala-Gly-Ala units. The fibroin of the silkworm is water-soluble and 
has a β-sheet conformation stabilized both by hydrogen bonding and van der Waals interactions 
between hydrophobic side chains.80, 81 To obtain a water-soluble form, the strong hydrogen bonds 
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need to be broken.77 After dialysis, the fibroin has a random-coil conformation that can undergo a sol-
gel transition by forming β-sheets.82 The gelation conditions of fibroin are mild and therefore suited 
for cell encapsulation. Very recently, Qi et al. published a review that summarizes various 
constructions of silk fibroin-based materials.83 Only two recent publications will be discussed below.  
Das et al. created a silk fibroin-gelatin bio-ink with encapsulated nasal inferior turbinate tissue-derived 
mesenchymal progenitor cells.84 Gelation could be controlled temporally by enzymatic and physical 
crosslinking. Optimization of different levels allowed the creation of 3D tissue constructs with a high 
cell viability directly after printing (~96%) and after 30 days of culture (~86%). The encapsulated stem 
cells showed multilineage differentiation to specific tissue over a 3 week culture study. Rodriguez et al. 
developed a silk-based ink in combination with gelatin as bulking agent and glycerol for physical 
crosslinking.85 The printed soft tissue resembling constructs remained intact up to three months, 
showed biocompatibility and promoted cellular infiltration and tissue integration. The optimal 
conditions of the ink included a minimum gelatin concentration of 10% w/v and a 1:1 ratio of silk to 
gelatin. Minimal inflammatory response was observed in a mouse model. 
Fibrin is a hemostatic agent used as a sealant in surgery. It has excellent biocompatibility, 
promotes cell attachment, and causes minimal inflammation and foreign body reactions.6 Fibrin gels 
are formed by the polymerization of fibrinogen monomers that is catalyzed by a thrombin solution. 
Depending on composition and ionic strength, their mechanical properties, gelation time, degradation 
time, and stability can be controlled.6 Fibrin can be used for wound healing as the fibrin network 
enables blood clotting by a crosslinking process preventing bleeding.86 The cell attachment property of 
fibrin promotes a high cell seeding efficiency and uniform cell distribution, however it suffers from 
long-term stability problems. Cui et al. created micro-capillaries by bioprinting human dermal 
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microvascular endothelial cells (HMVECs)-laden thrombin and a calcium solution on a fibrinogen 
substrate. The HMVECs then formed a capillary network after 21 culture days.87 Neural constructs can 
also be created by printing neural cells on fibrin.88 An in vitro study produced a printed urethra 
consisting of a PCL and PLCL scaffold and fibrin hydrogel. The printed structure containing urothelial 
cells and smooth muscle cells maintained a cell viability of over 80% over 7 days post-
printing[citation].89 
Alginate is a naturally occurring polysaccharide that is biocompatible, biodegradable and has a 
low toxicity.6 Alginate can crosslink through its polymeric backbone, which contains negatively 
charged carboxylate groups that can interact with positively charged calcium cations, yielding a 
crosslinked network.5  Alginate can be covalently crosslinked by reacting with poly(ethylene glycol)-
diamines, or cross-linked by phase transition.90 Alginate can also form a hydrogel by interaction with 
cells. Alginate modified with cell adhesion ligands can bind with cells to form a reversible, long-
distance network without chemical agents. These properties allow alginate and its derivatives to be 
used in various biomedical applications, like regenerative medicine, tissue engineering, and drug 
delivery. Munguia-Lopez et al. created a hydrogel composed of alginate, gelatin and carbon nanotubes 
(CNTs) to create bio-ink with tunable properties for a broad range of applications. An extrusion-based 
printer deposited the new bio-ink, yielding a highly porous material with a well-distributed layer of 
cells.91 Alginate can also be used in bone tissue engineering. Torres et al. tested the behavior of 
osteoblasts on β-tricalcium phosphate-hydroxyapatite scaffolds coated with alginate. The osteoblasts 
were able to adhere and proliferate on these scaffolds with a cell viability of approximately 100%.92 
Park et al. studied different compositions of high MW alginate (High Alg) and low MW alginate (Low 
Alg).93 They showed the successful construction of 3D scaffolds for 3 wt% High Alg and 1:2 Low Alg to 
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High Alg compositions. Constructs printed with fibroblasts showed high cell viability (~100%) and 
growth up to 7 days of culture. An alginate bio-ink was used by Xiong et al. to test the feasibility of 
gelatin as an energy absorbing layer in LIFT. An increased cell viability of 80% after printing compared 
to the control viability of 77% was observed.94 
Hyaluronic acid (HA) is a hydrophilic linear anionic polysaccharide composed of 1,3-β-D-
glucuronic acid and 1,4-β-N-acetyl-D-glucosamine.95 It can be found in most connective tissues in all 
living organisms. Currently, HA is used as a lubricant and in healthcare by preventing post-surgical 
adhesions.96 HA can only form a hydrogel when modified through esterification of the carboxyl or 
hydroxyl group and cross-linking.97 It is commonly modified with methacrylate groups which allows 
photocrosslinking.77 As HA is naturally present in tissues, it can be used to encapsulate cells. Ouyang et 
al. created a dual-cross-linking hydrogel using HA in combination with host-guest chemistry.98 
Adamantane was used as the guest and coupled to HA. The host, β-cyclodextrin, was separately 
coupled to HA. Both macromolecules were functionalized with methacrylate groups to enable 
photocrosslinking for a stronger gel. A shear-thinning hydrogel was created that is able to self-heal 
due to the employed host-guest chemistry. Host-guest chemistry allowed rapid stabilization straight 
after extrusion printing. Covalent photocrosslinking after printing increased stability to create a 
hydrogel stable up to one month. Further modifications can be made to the HA backbone, for 
instance, RGD was implemented to support cell adhesion. Very recently, Poldervaart et al. produced a 
hydrogel with increased storage and elastic moduli by UV irradiation of methacrylated HA.99 MSCs 
seeded within the hydrogel were able undergo osteogenic differentiation and maintained a cell 
viability of 64.4% over 3 weeks.  
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The natural polysaccharide agarose has a comparable gelation mechanism to gelatin.53 Its 
random coils transform into a double helix conformation when temperature reaches 30-40°C. 
Bertanossi et al. used fibres of agarose to create a vascular network within hydrogels. Endothelial cells 
were subsequently successfully infiltrated within the created micro-channels.100 A hybrid approach 
consisting of poly(D,L-lactic-co-glycolic acid) (PLGA) porous microspheres containing mouse fibroblasts 
and an agarose-collagen hydrogel was created by Tan et al.101 (Figure 5). The porous microspheres 
increased cell adhesion and proliferation before printing, while the use of collagen within the agarose 
hydrogel improved cell affinity and migration. After one and two weeks of culture, cells showed a 
viability of over 90%. Agarose can also be used in cartilage tissue engineering. Daly et al. tested four 
different hydrogels, namely agarose, alginate, GelMa and a commercially available PEG-methacrylate-
based hydrogel (BioINK™), on their printing properties and their capacity to support mesenchymal 
stem cells (MSCs) in their in vitro development to hyaline cartilage or fibrocartilage.102 All bio-inks 
showed a high cell viability post-printing (~80%). Agarose and alginate showed development of hyaline 
cartilage-like tissue, while GelMa and BioINK™ showed fibrocartilage-like tissue development. Gu et 
al. presented a bio-ink for the direct-write printing of human neural stem cells composed of alginate, 
carboxymethyl-chitosan (CMC), and agarose. The designed bio-ink undergoes rapid gelation through 
crosslinking, and forms a stable porous 3D neural mini-tissue construct.103 The cells were encapsulated 
by post-printing gelation giving a cell survival of around 75% directly after printing. The overall gel 
stiffness lies in the required range for brain tissue, and a porous and permeable gel that enhanced cell 
survival was obtained. This approach enables the characterization of neural cells during the study of 
neural development and function. 
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Carrageenan is a water-soluble polysaccharide consisting of β- and α-D-galactose.77 The 
amount of sulfate groups and their position determine the carrageenan family group.104 Only κ- and ι-
carrageenan form reversible hydrogels in the presence of cations through the transition from random-
coil to a double helix.105 The κ-carrageenan hydrogels are harder and less deformable than those from 
ι-carrageenan.106 Unfortunately, this polysaccharide is not biodegradable, making it an unfavorable 
material for in vivo applications.77 A thermo-responsive ink was made by Bakarich et al. through a 
synergistic crosslinking system consisting of κ-carrageenan, calcium ions, Jeffamine (poly(oxyalkylene 
amine)) and PEG diglycidyl ether to form κ-carrageenan/epoxy-amine ionic-covalent entanglement 
(ICE) hydrogels.107 The extrusion printed ink undergoes gelation upon a change in temperature as the 
κ-carrageenan forms a double helix. The single sulfate group on each κ-carrageenan repeating unit is 
crosslinked by calcium; the resulting network is entangled with the epoxy-amine polymer to form a 
tough reversible hydrogel. 
Methyl cellulose (MC), a derivative of the naturally occurring polysaccharide cellulose, is 
mostly used in pneumatic extrusion printers.14 Above the lower critical solution temperature (LCST), 
hydrophobic interactions within the MC chain become dominant, creating a network.108 The LCST of 
MC lies between 40-50°C. With the human body temperature at 37°C, MC can be used as a supporting 
material in tissue engineering.53 For instance, Fedorovich et al. made a 4% (w/v) MC hydrogel 
containing bone marrow stromal cells (BMSCs) to test 3D fiber deposition by the Bioplotter system 
with an overall cell viability of 80% post-printing.14 
The linear anionic polysaccharide gellan gum is composed of tetrasaccharide repeating 
units.109 Two forms exist that both transform from random-coils to double-helices upon cooling. The 
acetylated isoform forms soft gels, while the deacetylated one forms hard gels.110 The negatively 
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charged carboxyl side groups stop gel formation as the charges repel each other. Addition of cations 
allows shielding of the negative charges allowing gelation.77 The presence of the carboxyl groups can 
provide additional properties. When modified with methacrylate, the hydrogel becomes 
photocrosslinkable increasing stability.111 Lozano et al. used a gellan gum modified with RGD and 
combined with primary cortical neurons to form a bio-ink. This ink was used to print 3D brain-like 
structures with a cell viability of between 65 and 83% after printing. Modification with RGD increased 
cell proliferation and network formation.34  
Recently, Mueller et al. created a bio-ink for cartilage bioprinting based on alginate sulfate 
combined with nanocellulose to obtain rheological properties suitable for printing.112 The 
chondrocytes within the alginate sulfate-nanocellulose bio-ink showed cell migration, proliferation, 
and synthesis of the joint cartilage peptide collagen II before printing. After printing, performance was 
highly dependent on the nozzle geometry. Low extrusion pressure and shear stress produced 
migrating cells, but decreased cell proliferation. Conical needles with a wide diameter provided 3D 
structures with high shape fidelity and cell viability (>90%).  
 
Synthetic polymers 
Pluronics are ABA triblock copolymers consisting of hydrophilic PEG as the A block and 
hydrophobic polypropylene glycol (PPG) as the B block. Pluronic is a trademark poloxamer with many 
types that are mostly named with a letter followed by two or three digits. The letter stands for the 
physical state of the compound at room temperature; L for liquid, P for paste, and F for flake. The 
digits following this letter indicate the length and molecular weight (MW) of the Pluronic. The first one 
or two digits multiplied by 300 indicates the approximate MW of the hydrophobic block. The last digit 
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represents the PEG percentage in ten-fold. For instance, Pluronic F127, which is highly used in 
bioprinting, is a flaky solid at room temperature with a MW of approximately 3600 g/mol and 70% 
PEG content.53, 56 Block copolymers like Pluronic form micelles in solution when the temperature 
dependent critical micelle concentration (cmc) is reached. Below cmc, Pluronics occur as single chains 
in solution. When the concentration increases the hydrophobic blocks aggregate as a core creating a 
micelle at cmc. The packing of micelles causes the solution to undergo a phase transition to a gel, but 
also leads to a gel with poor mechanical strength. The cmc has an impact on the printability of 
Pluronics. Depending on the Pluronic used, concentration and temperature should be varied. Pluronic 
F127 requires a minimum of 20% w/v for gelation and is mostly extrusion- or valve-based printed at 
25-40% w/v.14, 113 The advantageous gelation temperature and good printability make Pluronics 
suitable for 3D printing. Because Pluronic is a synthetic polymer it shows no bioactivity and cannot be 
used for systems where long-term cell viability is needed.53 In 3D bioprinting it can therefore be used 
as a sacrificial layer.114 Gioffredi et al. characterized different Pluronic F127 hydrogels to select the 
optimal composition for bioprinting.115 Balb/3T3 fibroblasts loaded into the resulting bio-ink showed 
no decrease in cell viability after a 1 h printing session. To improve long-term cell viability and 
mechanical strength in Pluronic F127 hydrogels, Gioffredi et al. propose different options including 
coprinting with stabilizing agents. Pluronic F127 can also be used as a model ink to test mathematical 
models designed to improve printing resolution. Suntornnond et al. created a mathematical model for 
pneumatic extrusion-based bioprinting which they tested with Pluronic F127, which showed good 
agreement between experimental data and model predictions.116  
PEG can be used in different compositions for 3D bioprinting.53 It can be functionalized with 
diacrylate or dimethacrylate groups to create a photocrosslinkable polymer, and can be used to 
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fabricate hydrogels. Although there are few reports on printed PEG block copolymers, PEG is widely 
used as a crosslinker. PEG was used in combination with nanoclay by Hong et al. to create PEG-
alginate-nanoclay hydrogels with cell viability ranging from 75.5% to 86.0% over a 7 day culture 
period.117 The properties of each component resulted in a highly stretchable and tough hydrogel that 
could be used to create complex 3D structures. Censi et al. created a hydrogel by thermal gelation of 
an ABA triblock copolymer consisting of partially methacrylated poly(N-(2-
hydroxypropyl)methacrylamide lactate) and PEG, with the latter being the B block. For extra stability, 
the polymers where crosslinked by photopolymerization of the methacrylate groups. Encapsulated 
chondrocytes showed cell viabilities of ~94% and ~85% after 1 and 3 days, respectively.118 Very 
recently, Tseng et al. used PEG diacrylate (PEGDA) in a glucose-sensitive self-healing hydrogel to create 
vascularized constructs.119 A glucose-sensitive hydrogel composed of PEGDA plus dithiothreitol 
crosslinked with borax was used as a sacrificial material. To create the construct, a pattern of the 
PEGDA-dithiothreitol-borax hydrogel was embedded into a non glucose-sensitive hydrogel containing 
neural stem cells. By immersion into the glucose-containing culture medium, the sacrificial hydrogel 
was removed from the construct and a tubular channel was formed in the neural stem cell-containing 
hydrogel (Figure 6). Perfusion of vascular endothelial cells in the lumen of the channels covered the 
non-sacrificial hydrogel after migration and alignment after 3 days. A capillary-like structure was 
visible after 14 days. 
Another type of synthetic polymer used in 3D bioprinting is poly(N-isopropylacrylamide) 
(PNIPAAM),53 which has a gelation temperature of 30-37°C. In this temperature range, the PNIPAAM 
chains undergo a coil-globule transition and become hydrophobic; gelation occurs through 
hydrophobic interactions between these chains.120 To improve biocompatibility, PNIPAAM is mostly 
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combined with HA or alginate. Kesti et al. combined HA-PNIPAAM with HAMA to create high 
resolution scaffolds with high viability of bovine chondrocytes of 80% 3 hours post-printing and 97% 
after 4 days.31 
Poly(organophosphazenes) are synthetic polymers with a backbone of alternating nitrogen and 
phosphorus atoms with two organic side groups on almost all phosphorus atoms. The general formula 
is (N=PR1R2)n, where R1 and R2 represent the side groups.121 When the side groups are oligo-
ethyleneoxy groups, poly(organophosphazenes) can form biocompatible thermally responsive 
hydrogels that can be crosslinked through gamma-irradiation. Ionic crosslinks can be formed when 
oligo-ethyleneoxy and carboxyphenoxy side groups come in contact with di- or tri-valent cations.122 In 
conjugation with RGD, poly(organophosphazene) can be used to support MSC differentiation into 
osteogenic cell lines. Chun et al. covalently linked GRGDS to carboxylic acid-terminated 
poly(organophosphazene).123 Due to the liquid state of the conjugates at room temperature, the liquid 
could be injected in combination with rabbit MSCs into nude mice. At body temperature the 
conjugates formed a hydrogel. Osteogenesis markers increased and showed initiation of the 
maturation process after 4 weeks, indicating the promising use of the poly(organophosphazene)-
GRGDS conjugates in bone tissue engineering. In 2010, Park et al. made use of the injectability of 
poly(organophosphazene) to develop a protein release system. Protein diffusion was controlled by the 
incorporation of polyelectrolyte complexes (PECs) which formed electrostatic interactions with the 
proteins. The protein diffusion was dependent on the PECs, gel viscosity, and weight ratios of 
polycations and proteins. Overall, Park et al. showed the potential of the PEC-
poly(organophosphazene) hydrogel as a protein delivery system.124 A few years later the same group 
used the same system in combination with protamine sulfate to control the delivery of human growth 
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factor in rats.125 An increased growth rate was observed for the hydrogel in combination with daily 
injections of the growth factor for 7 days. Huang et al. included α-cyclodextrin (αCD) into mixed-
substituted polyphosphazenes to create a mechanically strong hydrogel for scaffold material by host-
guest chemistry and photocrosslinking.126 Polyphosphazene was substituted with either glycine ethyl 
ester groups (GlyEE) to promote cell affinity and biocompatibility, or acrylate-terminated PEG groups 
(PEGac) for self-assembly in the presence of αCD and preventing cell adhesion. After UV irradiation, a 
mechanically strong gel was formed with a high stability in water. By tuning the ratio GlyEE:PEGac the 
hydrogel could be tuned from cell-philic to cell-phobic. Due to the biocompatible nature and rapid sol-
gel transition of poly(organophosphazenes) they could be a promising group of materials for 3D 
bioprinting. 
 
Photocrosslinkable inks 
Crosslinking of inks enables a low viscosity solution with low shear stress during printing to 
protect cells and create a high resolution printable structure. To be able to do this, the polymers in the 
ink must be crosslinked quickly and be compatible with the emitted wavelength of the laser source.127 
Ouyang et al. introduced a new method to allow a longer crosslinking time with photocrosslinkable 
inks that do not polymerize fast enough for current approaches. They proposed a printing technique 
called “in-situ-crosslinking” in which a photo-permeable capillary was used to crosslink the ink 
seconds before deposition (Figure 7).128 To test their hypothesis, Ouyang et al. tested five 
photocrosslinkable inks: HAMA, GelMa, PEGDA and norbornene-functionalized HA (NorHA), which 
were UV-crosslinked with Irgacure 2959; and NorHA plus the photoinitiator lithium phenyl-2,4,6-
trimethylbenzoylphosphinate (LAP) and visible light. The new in-situ-crosslinking technique allowed 
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printing of high resolution structures with high cell viability from photocrosslinkable hydrogels, 
independent of ink viscosity. 
 
Microcarriers 
Microcarrier technology in combination with bioprinting allows cells to expand extensively 
while forming multi-cellular aggregates. Microcarriers also allow phenotypic control of the seeded 
cells.129 They do this by serving as substrates for anchorage-dependent cells.130 The materials used for 
these microcarriers can either be synthetic polymers, glass, or natural polymers such as cellulose, 
gelatin, or collagen. Due to their porous spherical morphology, cells can attach to the microcarrier 
surface and proliferate.16 The porous morphology also improves the transfer of gasses and nutrients, 
and allows a larger surface area for cell attachment.130 Levato et al. created a bio-ink containing MSC-
laden poly(lactic acid) microcarriers encapsulated in GelMa-gellan gum.129 The microcarrier-loaded 
printed structures had an increased compressive modulus and showed a high cell density, viability (60-
90%), cell adhesion, and osteogenic differentiation of the MSCs. The high microcarrier concentration 
in the GelMa-ink did not compromise the printability of the bio-ink. Jakob et al. developed a 
microcarrier-based 3D culture model of the epithelium.131 The microcarriers were porous Sephadex 
beads coated with denatured type I collagen to represent the epithelial basal lamella (Cytodex 3 
beads), enabling cells to attach through integrins and other transmembrane receptors. A fibroin 
microcarrier was used by Goncharenko et al. to study the influence of 3D culture and mineralization 
on osteoblast differentiation and actin skeleton reorganization.132 Mineralization and the use of fibroin 
microcarriers increased the expression of the osteogenesis marker alkaline phosphatase and changed 
the morphology of the actin filaments. 
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Cell aggregates 
Cell aggregate configurations form a scaffold-free alternative for bio-inks. Cell-cell interactions 
are of crucial importance in tissue formation. The type-I transmembrane protein cadherin causes 
multicellular aggregates for tissue morphogenesis.133 Cadherin allows intercellular adhesion which is 
important for cell-cell communication.16  
 
Tissue spheroids  
Tissue spheroids are spherical cell aggregates, generally 200-400 µm in diameter. They can be 
used as building blocks for tissue engineering or as tissue models for pharmaceutics.16 The self-
assembling cellular spheroids mimic developing tissue through fusion and reorganization.134 Most cells 
do not spontaneously aggregate in culture, rather they have to be induced to aggregate by some 
means. Different techniques exist for the generation of tissue spheroids, the most common of which 
uses cell-adhesion inert hydrogel moulds in which thousands to millions of cells are cultured in micro-
wells for 24-28 hours.16 At the bottom of the well, cells adhere to each other and form spheroids due 
to radial contraction and cadherin-mediated cytoskeletal reorganization.135 The hanging drop method 
uses gravity to concentrate the cells in one spot for cell aggregation. It is a simple technique that only 
requires a tissue culture plate and a cell suspension. A small drop of the cell suspension is pipetted on 
the plate, which is then inverted to make the droplet hang.136 Another technique uses a U-shaped trap 
of polydimethylsiloxane (PDMS) connected to a perfusion channel. Cells entrapped in the U-shape 
aggregate and are not prone to necrosis due to the flow of media and oxygen. It is, however, difficult 
to extract intact cell aggregates from the PDMS.16 Guo et al. recently used acoustic waves to assemble 
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cells on a membrane.137 The liquid overlay technique was used by Metzger et al. to generate tissue 
spheroids from fibroblasts and/or osteoblasts.138 They studied the cell-surface interaction between 
the spheroids and artificial ECMs. The artificial ECMs consisted of sulfated hyaluronan that was co-
fibrillised with collagen. The spheroid size changed depending on the sulfate level and the cell type, 
showing the usage of tissue spheroids for studies of cell-surface interactions. Magnetic 3D bioprinting 
was used by Tseng et al. to validate 3T3 fibroblast spheroid contraction in response to toxic 
compounds. Spheroid contraction assays could be used for the high-throughput screening of 
compounds in a 3D environment.139 
 
Cell pellets 
Cell pellets can be generated by centrifugal or gravitational forces. Generally, cell viability 
decreases after 24 hours due to a limited flow of medium and oxygen.16 The cell pellet can be 
transferred to a mould to improve cohesion through intercellular interactions. Cell pellets are mainly 
used in extrusion-based printing. Owens et al. bioprinted fully biological grafts to bridge nerve ends 
after nerve rupture.25 Cell pellets were used to form cellular cylinders that were deposited by a 
bioprinter into a support structure. Another bio-ink containing pellets of mouse embryonic fibroblasts 
was fabricated and used to create a scaffold-free macro-vascular structure for aortic tissue 
regeneration.140 
 
Tissue strands 
Tissue strands are cylindrical mini-tissues that can be used to produce tissue through 
bioprinting approaches. Akkouch et al. presented a method to scale-up the fabrication of tissue 
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strands with a cell viability of up to 94% 7 days after printing.135 Semi-permeable tubular alginate 
capsules were used to allow exchange between cells and the medium for nutrients and oxygen supply. 
Alginate capsules were extrusion-printed through coaxial printing of sodium alginate and a crosslinker 
solution. Cell pellets were injected into the alginate capsule till the capsule was tightly filled. The ends 
of the capsule were blocked during 5-7 days of culture for the aggregation of cells. The alginate 
capsule was then decrosslinked leaving the tissue strand. A heterocellular tissue strand could be 
fabricated through an overnight co-culture with a secondary cell type and fibronectin. Yu et al. 
presented a new method to print tissue strands without the need for a liquid delivery medium or 
moulding structure, giving a cell viability of 75% after printing, recovering to 87% after 7 days.45 Tissue 
strands as presented by Akkouch et al. were loaded into a unique print-head to rapidly fabricate tissue 
constructs. Cells used in this study were chondrocytes, which are known to prefer hypoxic 
conditions.141 Whether tissue strands with their low oxygen level in the core of the strand can be used 
for other tissue constructs needs to be explored. Yu et al. however, showed the use of tissue strands 
for cartilage formation.45 
 
Decellularized matrix components 
The protein composition of the ECM varies depending on the tissue it needs to support on a 
physical, chemical, structural, and biological level. The ECM can be harvested from various tissues and 
decellularized by extensive washing with surfactant, yielding a protein mixture for use as a bio-ink. It is 
important to use ECM from the tissue type that is intended to be recreated, as each ECM has different 
functionalities for each tissue.6 The dECM can be harvested from tissues like skin, adipose tissue,142 
cartilage,143 bone and heart.144, 145 The microenvironment is important for cellular differentiation and 
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function, therefore it is important that the dECM has the same properties as the ECM before 
decellularization. Singh et al. showed that a common decellularization protocol involving trypsin 
resulted in a severe loss of mechanical stiffness and collapse of the collagen architecture, leading to a 
decrease of porosity.146 Jang et al. were able to tailor the mechanical properties of dECM by 
photocrosslinking with vitamin B2. The resulting structures showed high viability (≥95%) and 
proliferation of cardiac progenitor cells.147 For harder material tissues, like bone and cartilage, ceramic 
materials or composite scaffolds are still needed to generate a mechanically stable scaffold.148 
 
APPLICATIONS 
Tissue engineering and regenerative medicine 
With donor numbers declining there is a need for tissue engineering and regenerative medicine to fill 
the void. Several tissues have already been explored for 3D bioprinting, including the heart valve, 
myocardial tissue, blood vessels, and musculo-skeletal tissues. For these tissues to be successful they 
have to provide the proper environment to allow cell proliferation and differentiation. Their elasticity, 
flexibility and recovery rate need to mimic that of the native tissue environment.18   
 Hard tissue engineering mostly focusses on creating bone and cartilage tissues for aging 
diseases and the musculoskeletal system.4 Scaffolds, which mostly consist of polymers, ceramics and 
hydrogels, are commonly used to allow tissue regeneration. Yu et al., however, were able to generate 
a scaffold-free structure using scalable tissue strands as a bio-ink for articular cartilage tissue.45 Gao et 
al. examined the ability of HA and bioactive glass (BG) nanoparticles to stimulate MSCs osteogenesis 
in a scaffold of PEG-dimethacrylate (DMA).149 The scaffold mixture was co-printed with HA and BG on 
a thermal inkjet printer. Both substances were polymerized simultaneously to achieve a highly 
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accurate placement. The scaffold containing HA showed the highest cell viability and improved 
mechanical characteristics.  Kelly’s group used an MSC-laden bio-ink and a PCL network to create 
templates with decoupled biological and mechanical functionality. They were able to fabricate a 
vertebral body with functional vasculature, and trabecular-like bone with a supporting marrow 
cavity.46 
 A great challenge in tissue engineering lies in the fabrication of cardiac tissues, due to the 
hierarchical structure of the myocardium and the need for angiogenesis. Zhang et al. created an 
endothelialized-myocardium-on-a-chip by combining bioprinting, microfluidics, and stem cells.59 Using 
a composite bio-ink, endothelial cells were printed together with a hydrogel to cover the inside of 
microfibers with endothelial cells. Cardiomyocytes were then seeded on the endothelial layer, 
generating a spontaneous and synchronous contracting myocardium.  
 To study the properties of neural networks and pathogenesis of neurological diseases, artificial 
neural tissues are engineered. Lee et al. patterned a multi-layered collagen gel with rat embryonic 
neurons to generate a flexible tool for artificial neural tissue.150 A year later, the same group 
constructed an artificial neural tissue of a vascular endothelial growth factor-releasing fibrin gel, 
collagen hydrogel, and murine neural stem cells.151 They showed migration of cells only occurred in 
the growth factor-containing cells compared to the controls.   
 
Transplantation and clinical applications 
Tissue engineering has been able to create multiple tissue types as in vitro models and for 
regenerative medicine applications. With the severe problem of tissue rejection after transplantation, 
3D bioprinting can assist by creating personalized tissues. The field has already been able to create 
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vascularized tissues, a challenge that still needs to be explored further. For personalized tissue 
transplants, 3D bioprinted structures need to resemble native tissues perfectly. DBB is a technique 
that can be used for the deposition of the bio-ink directly into the wound during surgery as it does not 
require contact and does not bear toxic or unsafe interventions.5 At this point, bioprinting cannot yet 
be used for human use. However, 3D printing has been used to treat the life-threatening condition of 
tracheobronchomalacia in an infant.152 Tracheobronchomalacia is a rare disease leading to the 
collapse of the central airways and respiratory insufficiency. After FDA approval and a written consent 
of the patient’s parents, Zopf et al. created a biodegradable airway splint out of PCL with a laser-
induced forward transfer printer. One year after the implantation of the customized tracheal splint, 
imaging showed a solid left mainstem bronchus without any complications. The splint is expected to 
be resorbed fully after 3 years. This procedure showed the possibilities for the combination of high-
resolution imaging, computer-aided design, and 3D bioprinting for personalized transplantation and 
clinical applications.  
 The ability of 3D printed constructs to direct tissue formation in vivo was also shown by Cooper 
et al.153 They demonstrated osteoblastic differentiation according to a bone morphogenetic protein-2 
(BMP-2) pattern in vitro and subsequent bone formation in vivo. In another in vivo study, Mooney et 
al. developed a polymeric system for the delivery of multiple growth factors for the development of 
tissues and organs.154 The generated system is able to deliver two or more growth factors, with a 
controlled dose and release mechanism. They demonstrated their system by delivering two growth 
factors for vascular development, leading to a mature vascular network in vivo.  
 Very recently, Jeon et al. were able to print hepatic 3D structures using alginate. They cultured 
human liver cancer cells (HepG2) on the alginate structure to test the feasibility of 3D bioprinting for 
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liver tissues. Extensive growth on the 3D model was observed compared to the 2D culture and 
structural aspects of the liver were exhibited better.155  Multiple studies have shown the great 
potential of 3D bioprinting for transplantation and clinical applications. As 3D bioprinting has many 
application areas, the FDA has provided guidance for its implementation in biomedical device 
manufacture.156 Another recent study included the 3D bioprinting of skin constructs for burn injuries. 
Cubo et al. printed human bilayered skin by using a bio-ink consisting of human plasma, primary 
human fibroblasts and keratinocytes obtained from skin biopsies.157 The printed construct has already 
been used to treat skin wounds of patients in Spain. They were able to create 100 cm2 of bilayered 
skin within 35 minutes. The printed constructs were indistinguishable from bilayered dermo-
epidermal equivalents. 
 
Drug testing and high-throughput screening  
The drug development process is extremely costly and it takes around ten years before a new drug 
gets regulatory approval. The approved drug is the only one of around 10,000 initial candidates that 
passes through all stages of the screening and regulatory process. Of all the drug candidates that make 
it to clinical trials, only one out of ten gets market approval.158 Failure of drug candidates in clinical 
trials can be caused by several reasons; low efficacy, toxicity, and adverse events, to name a few.159 
Currently, drugs are tested in 2D cell culture formats, followed by animal testing and clinical trials. 2D 
cell cultures do not represent the complex 3D nature of human tissues, making them non-predictive 
and unreliable.160 3D cell culture platforms together with perfusion culture technologies are creating 
more representative and predictive models of the behaviour of cells in vivo. A reliable human model is 
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needed to make drug discovery less costly and quicker. This model has to dismiss ineffective and toxic 
compounds as soon as possible.  
 3D bioprinting is able to generate 3D models containing human cells to create a 
microenvironment that most closely resembles the native environment, and facilitates cell-cell and 
cell-matrix interactions.161 These allow high-throughput screening of compounds to accelerate the 
drug discovery process. Li et al. created a 96 micro-scaffold array on a chip that enabled high 
throughput 3D cell culture, drug administration and quantitative in situ assays.162 Their microarray 
allows fast manual loading and with a total medium consumption in the microliter range. The group of 
Marsano created a clinically compatible fibrin/HA scaffold seeded with nasal chondrocytes that were 
functionalized with the FDA-approved drug bevacizumab to block vascular growth.163 Bevacizumab is 
known to sequestrate vascular endothelial growth factor from its environment. These scaffolds were 
able to block vessel in-growth in the host and enhanced the constructs’ survival rate by four-fold. 
 
Cancer research 
The ability of 3D bioprinting to mimic the native environment can also be used in the study of cancer 
pathogenesis and metastasis. The DBB technology can fabricate high-resolution tissue models with 
great repeatability.5 Xu et al. used DBB to build a 3D model for the investigation of multiple unknown 
regulatory feedback mechanisms between tumour and stromal cells.164 To do so, Matrigel was 
overlaid with human ovarian cancer cells, which spontaneously formed multicellular aggregates 
(acini).  The group of Zhang investigated a model for breast cancer metastasis.165 Bone is one of the 
primary sites where breast cancer metastasis occurs. Zhang et al. therefore developed a biomimetic 
bone matrix using stereolithography. Matrices consisted of osteoblasts or MSCs encapsulated in 
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nanocrystalline HA. Breast cancer cells were seeded on the matrices, enabling the study of their 
interaction. Breast cancer cells secreted more vascular endothelial growth factor compared to the 
control and the presence of the matrix cells enhanced their growth, while the cancer cells decreased 
the matrix cells proliferation. 
 
LIMITATIONS AND FUTURE PERSPECTIVES 
3D bioprinting has gained much interest in recent years, leading to a huge increase in the number of 
publications in the area. New technologies have been invented to overcome challenges set by other 
methods, and new improved approaches will be proposed in the future. The field is still at an early 
stage and there are still many challenges that need to be faced. One such challenge is the construction 
of whole organs. Organs are complex structures that need multiple cell types to be co-located, as well 
as sufficient mechanical strength to maintain shape and integrity.18 Printing resolution needs to be 
improved to fabricate structures with a complex inner architecture and 3D printed structures need to 
be implemented with a vascular network. 
Previous studies have generated vascular networks in vitro87 and in vivo.154  In 2011, 
Fedorovich et al. used endothelial progenitor cells (EPCs) and multipotent stromal cells to generate a 
heterogenous scaffold.8 While the multipotent stromal cells differentiated into a bone-like structure, 
the EPC layer allowed the formation of blood vessels. Different strategies have been used to improve 
vascularization since then; Yu et al. were able to create alginate-based well-defined vasculatures using 
human umbilical vein endothelial cells.166 They showed the ability of this vascular network to promote 
tissue maturation inside, but also to support the fibroblastic tissue self-assembly around it. Despite 
this promising progress, further improvement is still needed, as scaffold-free vascularization attempts 
  
41 
have been difficult to scale-up.24 A 3D printed structure of greater than 1 cm thickness, consisting of 
multiple cell types, was vascularized by Kolesky et al.167 This structure maintained its integrity and 
viability on a chip for more than six weeks. To achieve this, co-printing techniques were used to 
integrate parenchyma, stroma and endothelium into one structure.  
Some challenges lie in the key components of bioprinting, namely the bioprinter and the bio-
ink. The different forms of DBB all use a print-head to deposit a bio-ink. To create a technique that can 
print high resolution tissues with an even amount of cells, the droplet volume, the placement of these 
droplets, and the number of cells encapsulated in a droplet need to be controlled.5 Components need 
to be tuned to optimise the rheological properties of the bio-ink to allow precise printing whilst 
protecting the cells against shear forces, even at high cell concentrations. To be able to use bio-inks 
with viscosities for printing at sub-micrometre to micrometre resolution, the nozzle geometry needs 
to be altered as this restricts bio-ink viscosity and droplet size.5 Furthermore, bioprinted tissues and 
organs require further testing on their long-term stability and reliability. To overcome the restrictions 
of current print-heads and nozzles, new techniques have to be introduced.5  
An important component of a bio-ink are the cells, which need to be cultured in large amounts 
to be used for transplantation applications. The process to generate these can take weeks to months 
for each cell type.5 As human organs and tissues contain various types of cells,168 different cell types 
need to be cultured for a single organ or tissue. An advantage of bioprinting is the short time needed 
to print a structure, which should not be held back by the generation of its materials. Therefore, a 
technique needs to be developed to accelerate cell expansion times without harming the cells or 
increasing mutations.5  
  
42 
The post-printed structure needs to develop to a functional tissue construct gradually and 
successfully.4 Key factors to achieve a functional tissue construct are the cell response, stability of the 
printed structure, and ECM deposition.169 The microenvironment created by the ECM needs to allow 
differentiation and proliferation of the printed cells. To enable the ECM to guide stem cell 
differentiation, new materials need to be created to allow the ECM to send out signalling cues. As the 
biomimetic materials have to degrade to give way to the body’s own ECM, this degradation needs to 
be controlled to ensure the synthetic ECM is not degraded too rapidly or too slowly.134 The matrix 
component materials are also very important; they should support cell growth and create a substrate 
with mechanical and physical properties matching that of the native environment. New materials and 
printing mechanisms need to be developed to enable specific matrix phenotypes after bioprinting.170  
The mechanical strength of current synthetic ECMs, especially hydrogels, is weak. To 
strengthen the mechanical properties of hydrogels they can be co-printed with degradable and 
biocompatible support materials.5 To construct viable, large area and mechanically strong tissues, a 
capillary network needs to be implemented. Lee et al. used natural cellular mechanisms to overcome 
this problem.171 They created a microvascular bed between two large fluidic vessels, which were 
connected by angiogenic sprouting through a natural maturation process. Combining of support 
materials and vascular networks will provide the opportunity to create print heads with an extremely 
small nozzle orifice diameter.5 
For the mechanical strength of matrix components to be increased, fabrication time needs to 
decrease so that crosslinking can be induced sooner. However, shear stress is generated between the 
interior of the nozzle and the bio-ink components, including the cells.18 This induces cell damage 
which will increase with a decreasing fabrication time. Time is thus an important parameter in 3D 
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bioprinting. Consequently, 4D bioprinting, which allows 3D printed structures to change shape and 
functionality over time on application of an external stimulus, is becoming a key area of research.172 
This technique is expected to broaden the field of 3D bioprinting.  
 Many advances have occurred which will accelerate the future fabrication of functional human 
organs. Although the routine transplantation of tissues and organs is still some way ahead, other 
applications of 3D bioprinting can already be considered, for example the production of human tissue-
based models. This has opened the door to improved drug discovery and disease modelling. By using 
human induced-pluripotent stem cells derived from various patient groups, organ-on-a-chip models 
are enabled to take genetic variation into account for drug discovery.5 Furthermore, the tissue models 
and microarrays presented introduced science to a new era in pharmaceutics. Besides enabling high-
throughput screening with genetic variation, it also is not subjected to safety issues and ethical issues 
as in human patients.11  
 In cancer research, models have been proposed for the study of cancer pathogenesis and 
metastasis. A promising field of cancer research that is currently of significant interest is 
immunotherapy.11 Antibodies and antibody-recruiting molecules can enhance the immune response 
against tumours. These molecules can be implemented in 3D bioprinted delivery designs to fight 
tumours. Another possibility is to adjust a patient’s own cytotoxic T cells with chimeric antigen 
receptors (CARs).173 CARs are proteins on the T cell surface that recognize a specific protein on the 
tumour cell membrane. After modification these cytotoxic T cells can be transferred back to the 
patient, where they can induce apoptosis in tumour cells.  
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CONCLUSIONS 
 3D bioprinting has shown great capabilities in the fields of tissue engineering and regenerative 
medicine, transplantation and clinical applications, drug testing and high-throughput screening, and 
cancer research. To achieve further progress of 3D bioprinting, advancements must be made at all 
levels. Bioprinting technologies have to come up with new approaches to cope with the challenges 
given by current print-heads and nozzles, including printing resolution. New bio-ink materials need to 
be created to be able to fabricate long-term structural integer complexes with the final goal of 
creating functional whole human organ complexes. In the future, bioprinting standards need to be 
implemented to secure progress at each level.  3D bioprinting has made a start in changing healthcare 
strategies at the level of medical devices, clinical applications, and disease studies. It already has 
shown its capability in the design of complex architectures in 3D. As a rapidly developing field of 
research, the capabilities of 3D bioprinting will be expanded further leading to significant advances in 
science and better healthcare outcomes for patients. 
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ABBREVIATIONS 
3D: three-dimensional;  
αCD: α-cyclodextrin; 
AFS: amniotic fluid-derived;  
AM: additive manufacturing 
BG: bioactive glass;  
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BMP-2: bone morphogenetic protein-2; 
BMSC: bone marrow stromal cell; 
CAR: chimeric antigen receptor;  
cmc: critical micelle concentration; 
CMC: carboxymethylchitosan; 
CNT: carbon nanotube;  
CTAB: cetyltrimethylammonium bromide; 
dECM: decellularized extracellular matrix;  
DBB: droplet-based bioprinting; 
DMA: dimethacrylate;  
DOD: drop-on-demand;  
ECM: extracellular matrix;  
ELP: elastin-like peptide; 
ELR: elastin-like recombinamer; 
EPC: endothelial progenitor cell;  
FRESH: freeform reversible embedding of suspended hydrogels; 
GelMa: gelatin methacrylate; 
GlyEE: glycine ethyl ester; 
GNR: gold nanorods; 
HA: hyaluronic acid; 
HAMA: methacrylated hyaluronic acid; 
HepG2: human liver cancer cells;  
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High Alg: high molecular weight alginate; 
hMSCs: human mesenchymal stem cells; 
HMVEC: human dermal microvascular endothelial cell;  
ICE: ionic-covalent entanglement; 
ITOP: integrated tissue-organ printer;  
LAP: lithium phenyl-2,4,6-trimethylbenzoylphosphinate; 
LCST: lower critical solution temperature; 
LIFT: laser-induced forward transfer; 
Low Alg: low molecular weight alginate; 
MC: methyl cellulose; 
MMP: matrix metalloproteinase; 
MSC: mesenchymal stem cells; 
MW: molecular weight; 
NorHA: norbornene-functionalized hyaluronic acid; 
PDMS: polydimethylsiloxane; 
PEC: polyelectrolyte complex; 
PEG: poly(ethylene glycol);  
PEGac: acrylate-terminated poly(ethylene glycol); 
PEGDA: poly(ethylene glycol) diacrylate; 
PEGTA: 4-arm poly(ethylene glycol)-tetra-acrylate; 
PCL: poly(ε-caprolactone);  
PLGA: poly(D,L-lactic-co-glycolic acid); 
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PNIPAAM: poly(N-isopropylacrylamide); 
PPG: poly(propylene glycol); 
RGD: arginine-glycine-aspartic acid; 
Sol: colloidal solution. 
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Figure 1. Schematic representation of bioprinting technologies. (a) inkjet bioprinting includes 
continuous, drop-on-demand, and electrohydrodynamic jetting. (b) Extrusion-based printing. (c) Laser-
assisted (also known as laser-induced forward transfer) bioprinting. (d) Stereolithography. (e) 
Comparison of the techniques a-d. Figure reproduced with permission from 24, © Wolters Kluwer 
Health, Inc., 2016.  
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Figure 2. Droplet-based bioprinting. A1) Continuous ink jetting, A2) Thermal drop-on-demand inkjet 
bioprinting, A3) Piezoelectric drop-on-demand inkjet bioprinting, A4) Electrostatic drop-on-demand 
inkjet bioprinting, A5) Electrohydrodynamic jet bioprinting; B) Acoustic-droplet-ejection bioprinting; C) 
Micro-valve bioprinting. Reproduced with permission from 5, © Elsevier, 2016. 
  
  
56 
 
 
 
Figure 3. 3D bioprinted constructs by rapid continuous multimaterial extrusion bioprinting. A) Dual-
layered cuboid block, B) triple-layered cuboid block, C-E) blood-vessel like constructs of dual, triple, 
and quadruple materials, respectively, F) seven material-containing pyramid, G-H) continuous 
segments of seven different bio-inks in three- and ten-layered blocks, I) separately printed organ-like 
constructs from multiple bio-inks, stitched together for photograph, J-N) side views of constructs in 
‘I)’ to show 3D nature; J) brain, K) lung vascular, L) kidney, M) left atrium (heart), N) bladder/prostate. 
Reproduced with permission from 35, © John Wiley & Sons, 2016. 
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Figure 4. Summary of influential factors on printing fidelity and cells, and their relations critical to 
biofabrication. Reproduced with permission from 51, © John Wiley & Sons, 2013. 
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Figure 5. Schematic illustration of the fabrication of PLGA porous microspheres containing mouse 
fibroblasts in an agarose-collagen hydrogel. Mouse fibroblasts (in orange) are seeded on the 
microspheres. Stirred culturing allows infiltration and proliferation of the cells in the microspheres, 
creating cell-laden microspheres (CLMs). The CLMs are then encapsulated in the agarose-collagen 
hydrogel. This hydrogel undergoes gelation after printing on the chilled platform. Collagen fibrils form 
on culturing at 37°C. Reproduced from 101 under a Creative Commons CC-BY licence (authors: Y. J. Tan, 
X. P. Tan, W. Y. Yeong and S. B. Tor). 
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Figure 6. Fabrication of a vascularized construct using a glucose-sensitive self-healing hydrogel and a 
non-glucose sensitive cell-laden hydrogel. Culture medium dissolves glucose-sensitive hydrogel 
leading to tubular channels in non-glucose sensitive gel. Reproduced with permission from 119, © 
Elsevier, 2017. 
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Figure 7. Comparison of the “in-situ-bioprinting” approach to pre- and post-crosslinking approaches. 
Figure presents schematic representations of each approach (above) and nozzle deposition with the 
associated printed lattice structure (below). Reproduced with permission from 128, © John Wiley & 
Sons, 2016. 
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Table 1. Bio-ink material characteristics 
 
 BIODEGRADABLE?  INFLAMMATION CELL 
ATTACHMENT 
BIOPRINTING 
TECHNIQUEA 
CELL 
VIABILITY (%) 
LIMITATIONS REFS 
GELATIN Yes None Yes EB, PEI, 
2PP 
70-99.7% - 41, 56, 60, 
63, 64, 66, 
67 
HYALURONIC ACID Yes - Yes EB, PEI 64.4% Needs to be 
modified for 
gelation97  
98, 99  
AGAROSE Yes - Yes EB 60-90% - 100, 101, 
102, 103 
CARRAGEENAN No - - EB >80% Only two of 
the three 
family 
107, 174 
  
62 
members 
form gels105  
METHYL CELLULOSE Yes - No EB, MVB ~80-90% Can only be 
used as 
supporting 
material53 
13, 112 
COLLAGEN Yes None Yes MVB, 
EB, IBP, 
DOD, 
LBP 
46-99% - 9, 70, 71, 
72, 74, 75, 
76, 175 
CHITOSAN Yes - - EB ~75% - 103 
GELLAN GUM Yes - No EB 60-90% Only 
undergoes 
gelation by 
addition of 
cations77 
34, 129, 
176 
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ELASTIN Yes - Yes LBP - Hard to 
extract, 
synthetic 
counterpart 
is used77 
177 
SILK FIBROIN Yes None Yes EB, IBP, 
MVB 
70-96% Needs H-
bond 
breaking 
before 
usage77 
83, 84, 85, 
175, 178, 
179 
PLURONIC No - Yes EB, MVB 62-86% Only for 
short-term 
cell viability53 
14, 113, 
115, 116 
PEG Yes None No EB, MVB 75.5-94% Mostly used 
as crosslinker 
117, 118, 
119 
PNIPAAM No - - EB 80-97% Mostly 31 
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combined 
with HA or 
alginate for 
biocompatibil
ity53 
ALGINATE Yes None If modified with cell 
adhesion ligands 
EB, LIFT, 
MVB 
77-100% - 91, 92, 93, 
94, 112 
FIBRIN Yes Minimal Yes TIP, IBP, 
EB, LBP, 
LIFT, 
DOD 
74-100% Limited long-
term stability 
87, 88, 89, 
175, 180  
DECELLULARIZED 
ECM 
Yes None Yes EB ≥95% Decellularizat
ion can cause 
loss of 
mechanical 
strength146 
147, 148 
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A EB: extrusion-based; PEI: piezo-electric inkjet; 2PP: two-photon polymerization; MVB: micro-valve bioprinting; IBP: inkjet bioprinting; TIP: thermal 
inkjet printing; LBP: laser-based printing; DOD: drop-on-demand 
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